Catalyst Pharmaceutical Partners (CPRX)

[DonShimoda]

bw, we are range bound until the CPP-115 phase 1 results. Not unsurprisingly, both the cowen and roth presentations had little impact on the stock. The lack of float and small cap means CPRX is primarily a retail investor play at this point - some of whom will grow impatient. I believe that will change as additional data becomes available.